S Jhunjhunwala, G Raimondi, AW Thomson, SR … - Journal of Controlled …, 2009 - Elsevier Degradable microparticles have the potential to protect and release drugs over extended periods
and, if sized appropriately, can be passively targeted to phagocytic cells in vivo. Dendritic cells
(DC) are a class of phagocytic cells known to play important roles in transplant rejection. ... Cited by 1 - Related articles - All 3 versions
Y Yao, C Wang, RR Varshney, DA Wang - Pharmaceutical research, 2009 - Springer Received September 15, 2008; accepted October 28, 2008; published online November 18,
2008 Abstract. The use of antisense strategies such as ribozymes, oligodeoxynucleotides
(ODNs) and small interfering RNA (siRNA) in gene therapy, in conjunction with the use of ... Cited by 2 - Related articles - All 3 versions
B Phillips, N Giannoukakis, M Trucco - Expert Review of Clinical …, 2009 - ingentaconnect.com Dendritic cell (DC) immunotherapy is a clinical reality. Despite two decades of considerable data
demonstrating the feasibility of using DCs to prolong transplant allograft survival and to prevent
autoimmunity, only now are these cells entering clinical trials in humans. Type 1 diabetes ... Related articles - All 3 versions
MA Sperling - Pediatric Diabetes - interscience.wiley.com It is also possible that your web browser is not configured or not able to display style sheets.
In this case, although the visual presentation will be degraded, the site should continue to be
functional. We recommend using the latest version of Microsoft or Mozilla web browser to ... Related articles - All 2 versions
C Ionescu-Tîrgoviºte - Acta Endocrinologica (Buc), 2009 - 82.76.72.38 Abstract Based on epidemiological, clinic, biochemical and hormonal data (both personal and
international), our personal view is that natural history of autoimmune type 1 diabetes could include
the following stages: 1) The presence of a complex genetic predisposition towards β cell ... Related articles - View as HTML - All 2 versions
AP Acharya, MJ Clare-Salzler, BG Keselowsky - Biomaterials, 2009 - Elsevier Immunogenomic a combined with advances in adjuvant immunology are guiding progress toward
rational design of vaccines. Furthermore, drug delivery platforms (eg, synthetic particles) are
demonstrating promise for increasing vaccine efficacy. Currently there are scores of ... Related articles - All 2 versions